Lutetium (177Lu) vipivotide tetraxetan (progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) for patients who have progressed after treatment with AR pathway inhibition and taxane-based chemotherapy, in combination with androgen deprivation therapy (ADT))



  • Active Substance: Lutetium (177Lu) vipivotide tetraxetan
  • Name: Pluvicto®
  • Therapeutic area: Prostate cancer
  • Pharmaceutical company: Novartis Radiopharmaceuticals GmbH


Time table:

  • Start: 15.01.2023
  • Final decision by G-BA: 06.07.2023


Final decision:

a1. Adults for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or best supportive care represents the most appropriate patient-individual therapy: Indication for a considerable additional benefit

a2. Adults for whom cabazitaxel or olaparib represents the patient-individual therapy: No additional benefit proved.